The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody

Interleukin (IL)-6 plays essential roles not only in the immune response, but also in haematopoiesis and the central nervous system. Deregulated production of IL-6 has been found in chronic inflammatory autoimmune diseases, such as rheumatoid arthritis (RA), systemic onset juvenile idiopathic arthritis (soJIA), Crohn’s disease (CD) and systemic lupus erythematosus (SLE). Furthermore, IL-6 activities can explain many symptoms of these diseases. More importantly, serum levels of IL-6 are correlated with disease activity. Based on these facts, the authors planned to develop a humanised anti-IL-6 receptor antibody, tocilizumab (previously known as MRA), as a therapeutic agent for these inflammatory autoimmune diseases. Tocilizumab is a neutralising antibody to suppress IL-6 signalling mediated by both membranous and soluble IL-6R. Clinical efficacy of tocilizumab in RA, soJIA, adult-onset Still’s disease or CD patients has been discussed in this review. In all of these diseases, tocilizumab has improved the disease activity, suggesting that IL-6 plays an essential role in the pathogenesis of these diseases.

[1]  P. Woo,et al.  Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. , 2005, Arthritis and rheumatism.

[2]  T. Nomura,et al.  Distinct contribution of IL-6, TNF-alpha, IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice. , 2004, The Journal of clinical investigation.

[3]  N. Miyasaka,et al.  Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. , 2004, Arthritis and rheumatism.

[4]  T. Hibi,et al.  A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. , 2004, Gastroenterology.

[5]  K. Hagihara,et al.  Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. , 2003, Arthritis and rheumatism.

[6]  K. Yoshizaki,et al.  Influences of anti-mouse interleukin-6 receptor antibody on immune responses in mice. , 2002, Immunology letters.

[7]  K. Yoshizaki,et al.  Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still's disease. , 2002, Arthritis and rheumatism.

[8]  S. Sawhney,et al.  Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders , 2001, Archives of disease in childhood.

[9]  M. Neurath,et al.  Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo , 2000, Nature Medicine.

[10]  T. Kishimoto,et al.  IL-6 Is Required for the Development of Th1 Cell-Mediated Murine Colitis1 , 2000, The Journal of Immunology.

[11]  S. Nakae,et al.  Development of Chronic Inflammatory Arthropathy Resembling Rheumatoid Arthritis in Interleukin 1 Receptor Antagonist–Deficient Mice , 2000, The Journal of experimental medicine.

[12]  T. Kishimoto,et al.  Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. , 1998, Arthritis and rheumatism.

[13]  M. Suarez‐Almazor,et al.  Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. , 1998, The Journal of rheumatology.

[14]  Y. Ohsugi,et al.  IL‐6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice , 1998, Clinical and experimental immunology.

[15]  G. Kollias,et al.  Interleukin 6 Is Required for the Development of Collagen-induced Arthritis , 1998, The Journal of experimental medicine.

[16]  A. Martini,et al.  Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease? , 1998, The Journal of rheumatology.

[17]  Y. Kanai,et al.  Autoimmunity induction by human T cell leukemia virus type 1 in transgenic mice that develop chronic inflammatory arthropathy resembling rheumatoid arthritis in humans. , 1995, Journal of immunology.

[18]  M. Tsuchiya,et al.  Establishment of a novel myeloma cell line KPMM2 carrying t(3;14)(q21;q32), which proliferates specifically in response to interleukin-6 through an autocrine mechanism. , 1995, Leukemia.

[19]  J Saldanha,et al.  Humanization of a mouse anti-human interleukin-6 receptor antibody comparing two methods for selecting human framework regions. , 1994, Molecular immunology.

[20]  N. Udagawa,et al.  Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[21]  I. Takata,et al.  Enhanced expression of interleukin 6 in rat and murine arthritis models. , 1993, International journal of immunopharmacology.

[22]  J. Hyams,et al.  Relationship of functional and antigenic interleukin 6 to disease activity in inflammatory bowel disease. , 1993, Gastroenterology.

[23]  I. Takata,et al.  Effect of a novel anti-rheumatic drug, TA-383, on type II collagen-induced arthritis--suppressive effect of TA-383 on interleukin 6 production. , 1993, International journal of immunopharmacology.

[24]  R. Madhok,et al.  Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. , 1993, Annals of the rheumatic diseases.

[25]  M. Alarcón‐Riquelme,et al.  Age-dependent responsiveness to interleukin-6 in B lymphocytes from a systemic lupus erythematosus-prone (NZB x NZW)F1 hybrid. , 1992, Clinical immunology and immunopathology.

[26]  J. Schölmerich,et al.  Evidence for continuous stimulation of interleukin-6 production in Crohn's disease. , 1992, Gastroenterology.

[27]  D. Kioussis,et al.  Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. , 1991, The EMBO journal.

[28]  C. Gordon,et al.  Urinary IL‐6: a marker for mesangial proliferative glomerulonephritis? , 1991, Clinical and experimental immunology.

[29]  M. Linker-Israeli,et al.  Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. , 1991, Journal of immunology.

[30]  K. Tanikawa,et al.  Significance of interleukin-6 in patients with inflammatory bowel disease , 1991, Gastroenterologia Japonica.

[31]  A. Fontana,et al.  Interleukin-6 is elevated in plasma in multiple sclerosis , 1991, Journal of Neuroimmunology.

[32]  L. Neckers,et al.  Characterization of an interleukin-6-mediated autocrine growth loop in the human multiple myeloma cell line, U266. , 1991, Blood.

[33]  T. Hirano,et al.  Molecular cloning and expression of an IL-6 signal transducer, gp130 , 1990, Cell.

[34]  Y. Koishihara,et al.  Immunologic abnormality in NZB/W Fl mice. Thymus‐independent expansion of B cells responding to interleukin‐6 , 1990, Clinical and experimental immunology.

[35]  S. Hirohata,et al.  Elevated levels of interleukin-6 in cerebrospinal fluid from patients with systemic lupus erythematosus and central nervous system involvement. , 1990, Arthritis and rheumatism.

[36]  J V Castell,et al.  Interleukin-6 and the acute phase response. , 1990, The Biochemical journal.

[37]  H. Hatanaka,et al.  Interleukin-6 as a neurotrophic factor for promoting the survival of cultured basal forebrain cholinergic neurons from postnatal rats , 1989, Neuroscience Letters.

[38]  T. Hirano,et al.  Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130 , 1989, Cell.

[39]  S. Burstein,et al.  Human interleukin 6 is a direct promoter of maturation of megakaryocytes in vitro. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[40]  D. P. Murphy,et al.  Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[41]  J. Lotem,et al.  The Molecular Regulators of Macrophage and Granulocyte Development , 1989, Annals of the New York Academy of Sciences.

[42]  P. Guerne,et al.  Synovium as a source of interleukin 6 in vitro. Contribution to local and systemic manifestations of arthritis. , 1989, The Journal of clinical investigation.

[43]  T. Hirano,et al.  Excessive production of interleukin 6/B cell stimulatory factor‐2 in rheumatoid arthritis , 1988, European journal of immunology.

[44]  H. Imura,et al.  Interleukin-6 stimulates the secretion of adrenocorticotropic hormone in conscious, freely-moving rats. , 1988, Biochemical and biophysical research communications.

[45]  T. Taniguchi,et al.  Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor. , 1988, Science.

[46]  T. Hirano,et al.  Induction of neuronal differentiation in PC12 cells by B-cell stimulatory factor 2/interleukin 6 , 1988, Molecular and cellular biology.

[47]  F. Houssiau,et al.  Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. , 1988, Arthritis and rheumatism.

[48]  T. Hirano,et al.  B cell stimulating factor 2/interleukin 6 is a costimulant for human thymocytes and T lymphocytes , 1988, The Journal of experimental medicine.

[49]  A Muraguchi,et al.  The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells , 1988, The Journal of experimental medicine.

[50]  J. Ihle,et al.  Interleukin 6 enhancement of interleukin 3-dependent proliferation of multipotential hemopoietic progenitors. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[51]  R. Simpson,et al.  Purification and characterization of human fibroblast-derived hybridoma growth factor identical to T-cell-derived B-cell stimulatory factor-2 (interleukin-6). , 1987, European journal of biochemistry.

[52]  P. Lansdorp,et al.  Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[53]  T. Taniguchi,et al.  Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin , 1986, Nature.

[54]  J H Korn,et al.  Structure and expression of cDNA and genes for human interferon‐beta‐2, a distinct species inducible by growth‐stimulatory cytokines. , 1986, The EMBO journal.

[55]  G. Volckaert,et al.  Structural analysis of the sequence coding for an inducible 26-kDa protein in human fibroblasts. , 1986, European journal of biochemistry.

[56]  P. Emery,et al.  Efficacy of IL-6 receptor antagonist Mra in rheumatoid arthritis patients with an incomplete response to methotrexate (CHARISMA). , 2003 .